OptiBiotix Health (OPTI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

13.33p
   
  • Change Today:
      0.83p
  • 52 Week High: 33.00p
  • 52 Week Low: 10.25p
  • Currency: UK Pounds
  • Shares Issued: 97.94m
  • Volume: 1,312,755
  • Market Cap: £13.06m
  • Beta: 0.59

OptiBiotix inks ingredient deal with Tata Chemicals

By Josh White

Date: Monday 23 Oct 2023

LONDON (ShareCast) - (Sharecast News) - Life sciences developer OptiBiotix Health announced a significant agreement with Tata Chemicals on Monday, that would see its proprietary 'Fossence' product incorporated into their 'SlimBiome' and 'LeanBiome' product lines, specifically tailored for the Indian market.
The AIM-traded firm said the deal would see Tata's Fossence - a proprietary short chain fructo-oligosaccharide (FOS) - into OptiBiotix's SlimBiome and LeanBiome products, customised to cater to the demands of the Indian consumer base.

It said Fossence would directly replace the FOS currently used in SlimBiome products available in other markets.

The board said the integration was a strategic move grounded in scientific substantiation, aiming to bring forth the well-documented health benefits of FOS to the Indian market.

It said Tata Chemicals, listed on the Indian stock exchange, is an integral part of the Tata Group, which employs over one million people and recorded annual revenue of around $300bn in 2022.

As part of the collaboration, Tata Chemicals granted approval for the incorporation of the Fossence logo on products containing SlimBiome in India, introducing a branded ingredient from a reputable source to Indian consumers.

"We are pleased to report this agreement with Tata Chemicals which creates the opportunity to bring products containing Tata's proprietary Fossence in SlimBiome and LeanBiome to the Indian market," said chief executive officer Stephen O'Hara.

"Tata Chemicals is one of India's leading suppliers of food ingredients with many well-known and respected brands.

"Fossence's established health benefits with Indian consumers and its trusted brand combined with SlimBiome's strong science, clinical studies, and excellent customer reviews will help reduce hunger and food cravings to support the weight management efforts of India's 135 million obese men and women."

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OPTI Market Data

Currency UK Pounds
Share Price 13.33p
Change Today 0.83p
% Change 6.67 %
52 Week High 33.00p
52 Week Low 10.25p
Volume 1,312,755
Shares Issued 97.94m
Market Cap £13.06m
Beta 0.59

OPTI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
1.11% above the market average1.11% above the market average1.11% above the market average1.11% above the market average1.11% above the market average
44.00% above the sector average44.00% above the sector average44.00% above the sector average44.00% above the sector average44.00% above the sector average
Price Trend
71.69% below the market average71.69% below the market average71.69% below the market average71.69% below the market average71.69% below the market average
38.78% below the sector average38.78% below the sector average38.78% below the sector average38.78% below the sector average38.78% below the sector average
Income Not Available
Growth
83.59% below the market average83.59% below the market average83.59% below the market average83.59% below the market average83.59% below the market average
88.24% below the sector average88.24% below the sector average88.24% below the sector average88.24% below the sector average88.24% below the sector average

OPTI Dividends

No dividends found

Trades for 25-Nov-2024

Time Volume / Share Price
13:04 7,000 @ 13.31p
11:54 14,955 @ 13.33p
11:37 50,000 @ 13.11p
11:36 55,000 @ 13.21p
11:35 2,920 @ 13.21p

OPTI Key Personnel

CEO Stephen O'Hara
Finance Director Graham Myers

Top of Page